zPREDICTA Patents

Patent portfolio assigned to zPREDICTA (verified via public assignee records). Estimated patent count: 3. Tumor-specific 3D cell culture models for cancer drug testing (founded 2014; acquired by Predictive Oncology Dec 2021). Has patents (US20190169562A1 assigned to Zpredicta Inc; related 3D cell culture patents US9334473B2 / WO2015158777A1 by founder Julia Kirshner) - count is an estimate. Strategic collaborations with LabCorp/Covance and Science Exchange (B2B partners, not consumer customers). No direct-competitor list confirmed from a fetched page.